Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | MITF | O75030 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | PHGDH | O43175 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.51 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3665346 | 0.87 | KMT2A (0.61) | MAPTL3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL1843232 | 0.83 | MAPT (0.68) | MAPTL3MBTL1MEN1KMT2APOLB | |
| SCHEMBL7164868 | 0.82 | MAPT (0.84) | MAPTL3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL102602 | 0.81 | MAPT (0.77) | MAPTL3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL1841977 | 0.80 | APP (0.58) | MAPTNPC1MEN1KMT2ARAB9A | |
| SCHEMBL641989 | 0.79 | PHGDH (0.77) | MAPTL3MBTL1NPC1MEN1KMT2A | |
| N-Phenylbenzamide SCHEMBL28793783 | 0.79 | MEN1 (0.71) | MAPTL3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL1844781 | 0.78 | APP (0.61) | MAPTNPC1MEN1KMT2ARAB9A | |
| SCHEMBL10055047 | 0.78 | MAPT (0.73) | MAPTL3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL9689325 | 0.77 | MAPT (0.63) | MAPTL3MBTL1NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436031-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| EP-2139474-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Paratek Pharmaceuticals, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20090170812-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090131481-A1 | Transcription Factor Modulating Compounds and Methods of Use Thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2009005551-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-1742637-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Paratek Pharmaceuticals, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20060160799-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006076009-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | MAPT 4415/4885L3MBTL1 573/4885NPC1 3055/4885 |
| US-20060160799-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | MAPT 4415/4885L3MBTL1 573/4885NPC1 3055/4885 |
| US-20090131481-A1 | Transcription Factor Modulating Compounds and Methods of Use Thereof | CREBBP, JUN, IRF3 | MAPT 4703/4885L3MBTL1 244/4885NPC1 3138/4885 |
| US-20090170812-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | MAPT 4415/4885L3MBTL1 573/4885NPC1 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.